Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 290 articles:
HTML format

Single Articles

    March 2023
  1. JURADO R, Aren M, Sorigue M
    Should WE use flow cytometry to assess bone marrow involvement by lymphoma?
    Leuk Lymphoma. 2023 Mar 8:1-3. doi: 10.1080/10428194.2023.2186730.

  2. AL ZAKI A, McCurry D, Strati P
    CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy.
    Leuk Lymphoma. 2023 Mar 8:1-8. doi: 10.1080/10428194.2023.2185090.
    PubMed     Abstract available

    February 2023
  3. XU W, Yang S, Zhou K, Pan L, et al
    Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
    Leuk Lymphoma. 2023 Feb 17:1-5. doi: 10.1080/10428194.2022.2164692.

  4. OWATARI S, Tokunaga M, Nakamura D, Uozumi K, et al
    A decrease in newly diagnosed patients with adult T-cell leukemia/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan.
    Leuk Lymphoma. 2023 Feb 10:1-9. doi: 10.1080/10428194.2023.2173524.
    PubMed     Abstract available

  5. VAN LE H, Van Naarden Braun K, Nowakowski GS, Sermer D, et al
    Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
    Leuk Lymphoma. 2023 Feb 8:1-13. doi: 10.1080/10428194.2022.2160200.
    PubMed     Abstract available

    January 2023
  6. LIN M, Wu X, Zhang L, Li L, et al
    Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
    PubMed     Abstract available

  7. GAUT D, Oliai C, Mead M
    Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series.
    Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.

  8. QUALLS D, Noy A, Straus D, Matasar M, et al
    Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
    Leuk Lymphoma. 2023 Jan 15:1-4. doi: 10.1080/10428194.2022.2164194.

  9. KALOYANNIDIS P, Al Zayer M, Al Darweesh M, Al Batran M, et al
    Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Jan 11:1-4. doi: 10.1080/10428194.2022.2164195.

  10. RUSCONI C, Visco C
    Putting the brain into mantle cell lymphoma.
    Leuk Lymphoma. 2023 Jan 2:1-2. doi: 10.1080/10428194.2022.2163171.

  11. AMAADOR K, Kersten MJ, Minnema MC, Vos JMI, et al
    Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Leuk Lymphoma. 2023;64:30-41.
    PubMed     Abstract available

    December 2022
  12. FRONTZEK F, Hailfinger S, Lenz G
    Plasmablastic lymphoma: from genetics to treatment.
    Leuk Lymphoma. 2022 Dec 28:1-9. doi: 10.1080/10428194.2022.2162341.
    PubMed     Abstract available

  13. SIMBA K, Mohamed Z, Opie JJ, Andera LF, et al
    The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Dec 23:1-8. doi: 10.1080/10428194.2022.2157214.
    PubMed     Abstract available

  14. PLUMPTRE IR, Said JT, Sun T, Larocca C, et al
    Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review.
    Leuk Lymphoma. 2022;63:2832-2846.
    PubMed     Abstract available

  15. BROGLIO K, Kostakoglu L, Ward C, Mattiello F, et al
    PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design.
    Leuk Lymphoma. 2022;63:2816-2831.
    PubMed     Abstract available

  16. WANG P, Xu L, Fan Y, Li B, et al
    EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
    Leuk Lymphoma. 2022;63:3370-3377.
    PubMed     Abstract available

  17. JOSHI U, Bhattarai A, Gaire S, Gill S, et al
    Risk of second primary malignancy in patients with primary myelofibrosis: a SEER database study.
    Leuk Lymphoma. 2022;63:3456-3461.
    PubMed     Abstract available

  18. MAJOR A, Wright R, Hlubocky FJ, Smith SM, et al
    Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance.
    Leuk Lymphoma. 2022;63:3331-3339.
    PubMed     Abstract available

  19. TERAO T, Tsushima T, Ikeda D, Fukumoto A, et al
    Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
    Leuk Lymphoma. 2022;63:3394-3401.
    PubMed     Abstract available

  20. FRIED S, Shouval R, Varda-Bloom N, Besser MJ, et al
    Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.
    Leuk Lymphoma. 2022;63:3385-3393.
    PubMed     Abstract available

    November 2022
  21. GU L, Oh Y, Smith MP, Kurtansky NR, et al
    The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma.
    Leuk Lymphoma. 2022 Nov 26:1-3. doi: 10.1080/10428194.2022.2131418.

  22. MULLIGAN SP, Opat S, Cheah CY, Kuss B, et al
    Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
    Leuk Lymphoma. 2022 Nov 24:1-7. doi: 10.1080/10428194.2022.2148220.
    PubMed     Abstract available

  23. MILLS GS, Di Ciaccio PR, Tang C, Chadwick V, et al
    Capturing the lived experiences of women with lymphoma in pregnancy: a qualitative study.
    Leuk Lymphoma. 2022 Nov 24:1-10. doi: 10.1080/10428194.2022.2148376.
    PubMed     Abstract available

  24. MCLAUGHLIN N, Wang Y, Witzig T, Villasboas J, et al
    Central nervous system involvement by mantle cell lymphoma.
    Leuk Lymphoma. 2022 Nov 23:1-7. doi: 10.1080/10428194.2022.2148211.
    PubMed     Abstract available

  25. YANG H, Bollu V, Lim S, Tesfaye M, et al
    Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy - a retrospective cohort study using CMS 100% Medicare claims database.
    Leuk Lymphoma. 2022 Nov 21:1-10. doi: 10.1080/10428194.2022.2147395.
    PubMed     Abstract available

  26. FENLON JB, Hutten RJ, Johnson SB, Hu B, et al
    Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era.
    Leuk Lymphoma. 2022 Nov 21:1-8. doi: 10.1080/10428194.2022.2148215.
    PubMed     Abstract available

  27. KURUVILLA J, Armand P, Hamadani M, Kline J, et al
    Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
    Leuk Lymphoma. 2022 Nov 18:1-10. doi: 10.1080/10428194.2022.2136956.
    PubMed     Abstract available

  28. KISERUD CE, Lockmer S, Baerug I, Dahl AA, et al
    Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma - a comparison with normative data.
    Leuk Lymphoma. 2022 Nov 7:1-7. doi: 10.1080/10428194.2022.2142050.
    PubMed     Abstract available

  29. TYRYSHKIN K, Moore A, Good D, Popov J, et al
    Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy.
    Leuk Lymphoma. 2022 Nov 6:1-11. doi: 10.1080/10428194.2022.2136968.
    PubMed     Abstract available

  30. SALVARIS RT, Cheah CY
    Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?
    Leuk Lymphoma. 2022 Nov 4:1-3. doi: 10.1080/10428194.2022.2142057.

  31. PARK E, Lee C, Park J, Liu J, et al
    Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
    Leuk Lymphoma. 2022 Nov 4:1-12. doi: 10.1080/10428194.2022.2140282.
    PubMed     Abstract available

  32. CORTESE MJ, Wei W, Cerdena S, Watkins MP, et al
    A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
    Leuk Lymphoma. 2022 Nov 2:1-12. doi: 10.1080/10428194.2022.2140281.
    PubMed     Abstract available

  33. LAURENGE A, Ursu R, Tabouret E, Harlay V, et al
    SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era.
    Leuk Lymphoma. 2022 Nov 1:1-4. doi: 10.1080/10428194.2022.2131420.

  34. WYSOCKA M, Jariwala N, Zhang K, Benoit B, et al
    TCF1 and Tox define different subsets of CD4 T cells in patients with Sezary syndrome.
    Leuk Lymphoma. 2022;63:2715-2718.

    October 2022
  35. LIPSCOMB J, Switchenko JM, Flowers CR, Gillespie TW, et al
    Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia.
    Leuk Lymphoma. 2022 Oct 28:1-10. doi: 10.1080/10428194.2022.2133539.
    PubMed     Abstract available

  36. SHAH NN, Castillo-Tokumori F, Whiting J, Boulware D, et al
    Frontline treatment approaches in TP53-aberrant mantle cell lymphoma.
    Leuk Lymphoma. 2022 Oct 27:1-4. doi: 10.1080/10428194.2022.2131407.

  37. MO SS, Cleveland J, Rubenstein JL
    Primary CNS lymphoma: update on molecular pathogenesis and therapy.
    Leuk Lymphoma. 2022 Oct 26:1-9. doi: 10.1080/10428194.2022.2133541.
    PubMed     Abstract available

  38. GARDENSWARTZ A, Mehta B, El-Mallawany NK, van de Ven C, et al
    Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, a
    Leuk Lymphoma. 2022 Oct 19:1-4. doi: 10.1080/10428194.2022.2133542.

  39. ARDISSON KORAT AV, Chiu YH, Bertrand KA, Zhang S, et al
    A prospective analysis of red blood cell membrane polyunsaturated fatty acid levels and risk of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Oct 18:1-11. doi: 10.1080/10428194.2022.2131419.
    PubMed     Abstract available

  40. VERGOTE VKJ, Verhoef G, Janssens A, Woei-A-Jin FJSH, et al
    [(18)F]FDG-PET/CT volumetric parameters can predict outcome in untreated mantle cell lymphoma.
    Leuk Lymphoma. 2022 Oct 12:1-10. doi: 10.1080/10428194.2022.2131415.
    PubMed     Abstract available

  41. IRIYAMA N, Miura K, Takahashi H, Nakagawa M, et al
    Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience.
    Leuk Lymphoma. 2022 Oct 12:1-7. doi: 10.1080/10428194.2022.2131426.
    PubMed     Abstract available

  42. MA G, Gao Y, Jing X, He C, et al
    Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
    Leuk Lymphoma. 2022 Oct 10:1-11. doi: 10.1080/10428194.2022.2131427.
    PubMed     Abstract available

  43. KOSYDAR S, Ansell SM
    Long-term outcomes for patients with Hodgkin lymphoma at increased risk of progression or relapse.
    Leuk Lymphoma. 2022 Oct 10:1-13. doi: 10.1080/10428194.2022.2131422.
    PubMed     Abstract available

  44. FERHANOGLU B, Kim TM, Karduss A, Brittain D, et al
    Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study.
    Leuk Lymphoma. 2022 Oct 6:1-14. doi: 10.1080/10428194.2022.2126281.
    PubMed     Abstract available

  45. PARSONS MW, Wada DA, Halwani AS, Tao R, et al
    Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study.
    Leuk Lymphoma. 2022;63:2428-2435.
    PubMed     Abstract available

    September 2022
  46. HWANG HS, Sung HJ, Kim MJ, Yoon DH, et al
    Extra copy number of BCL2 is correlated with increased BCL-2 protein expression and poor survival in diffuse large B-cell lymphoma treated with chemoimmunotherapy.
    Leuk Lymphoma. 2022 Sep 27:1-10. doi: 10.1080/10428194.2022.2113525.
    PubMed     Abstract available

  47. MANJI F, Bhella S, Kridel R, Kukreti V, et al
    Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma.
    Leuk Lymphoma. 2022 Sep 27:1-7. doi: 10.1080/10428194.2022.2123226.
    PubMed     Abstract available

  48. WANG W, Gehris BT, Mai B, Chen L, et al
    HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation.
    Leuk Lymphoma. 2022 Sep 26:1-4. doi: 10.1080/10428194.2022.2123233.

  49. LIU J, Wei J, Jiang X, Yu W, et al
    Prognostic effects of clinical parameters, genetic abnormalities, and subtypes in primary gastric diffuse large B-cell lymphoma: a cohort analysis of 146 patients.
    Leuk Lymphoma. 2022 Sep 23:1-8. doi: 10.1080/10428194.2022.2126279.
    PubMed     Abstract available

  50. ZIBARA V, Sen F, Scordo M, Falchi L, et al
    Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
    Leuk Lymphoma. 2022 Sep 18:1-4. doi: 10.1080/10428194.2022.2113528.

  51. ZDUNIAK A, Leveque E, Perdrix A, Etancelin P, et al
    Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
    Leuk Lymphoma. 2022 Sep 18:1-11. doi: 10.1080/10428194.2022.2123222.
    PubMed     Abstract available

  52. DABAJA BS, Ng AK
    Let us give our Hodgkin's lymphoma patients the radiation they need.
    Leuk Lymphoma. 2022 Sep 15:1-2. doi: 10.1080/10428194.2022.2123237.

  53. BEHDAD A, Schipma MJ, Ma S, Chen YH, et al
    Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10.
    Leuk Lymphoma. 2022 Sep 14:1-5. doi: 10.1080/10428194.2022.2123236.

  54. WATSON LR, Lew TE, Fox LC, Khot A, et al
    Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma.
    Leuk Lymphoma. 2022 Sep 7:1-5. doi: 10.1080/10428194.2022.2118537.

  55. PASVOLSKY O, Berger T, Geiger KR, Akirov A, et al
    Infectious complications and long-term outcomes in patients with diffuse large B-Cell lymphoma and diabetes mellitus.
    Leuk Lymphoma. 2022 Sep 6:1-7. doi: 10.1080/10428194.2022.2118526.
    PubMed     Abstract available

  56. NOLAN J, Murphy C, Dinneen K, Lee G, et al
    p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.
    Leuk Lymphoma. 2022 Sep 5:1-4. doi: 10.1080/10428194.2022.2118529.

  57. OLUWOLE OO, Chen JMH, Chan K, Patel AR, et al
    Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
    Leuk Lymphoma. 2022 Sep 1:1-11. doi: 10.1080/10428194.2022.2113526.
    PubMed     Abstract available

  58. KATZ DA, Morris JD, Chu MP, David KA, et al
    Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.
    Leuk Lymphoma. 2022;63:2063-2073.
    PubMed     Abstract available

  59. FERRAD M, Ghazzaui N, Issaoui H, Drouineau E, et al
    Homozygous iMycCalpha transgenic mice as a model of plasma B-cell lymphomas.
    Leuk Lymphoma. 2022;63:2114-2125.
    PubMed     Abstract available

  60. MARTINI DJ, Goyal S, Switchenko JM, Lechowicz MJ, et al
    African American and Caucasian patients with Sezary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
    Leuk Lymphoma. 2022;63:2094-2101.
    PubMed     Abstract available

    August 2022
  61. STAMATOULLAS A, Ghesquieres H, Feugier P, Andre M, et al
    Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
    Leuk Lymphoma. 2022 Aug 17:1-9. doi: 10.1080/10428194.2022.2107204.
    PubMed     Abstract available

  62. KUMAR A, Casulo C, Joffe E, Moskowitz C, et al
    Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
    Leuk Lymphoma. 2022 Aug 16:1-8. doi: 10.1080/10428194.2022.2109155.
    PubMed     Abstract available

  63. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    PubMed     Abstract available

  64. CHOHAN KL, Ansell SM
    The broader prospects for bispecifics in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Aug 3:1-3. doi: 10.1080/10428194.2022.2107205.

  65. SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
    Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
    PubMed     Abstract available

  66. HUGHES MS, Sterling CH, Varadhan R, Ambinder RF, et al
    Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study.
    Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105330.

  67. SERRANO LOPEZ J, Jimenez-Jimenez C, Chutipongtanate S, Serrano J, et al
    High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies.
    Leuk Lymphoma. 2022;63:1861-1870.
    PubMed     Abstract available

    July 2022
  68. WEIL CR, Parsons MJ, Hutten RJ, Lew FH, et al
    Patterns of care and outcomes of early stage I-II Hodgkin lymphoma treated with or without radiation therapy.
    Leuk Lymphoma. 2022 Jul 29:1-11. doi: 10.1080/10428194.2022.2105325.
    PubMed     Abstract available

  69. DAVIDSON MB, Rice A, Stewart D, Owen C, et al
    Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study.
    Leuk Lymphoma. 2022 Jul 25:1-4. doi: 10.1080/10428194.2022.2102620.

  70. GUAN T, Lo M, Young R, Ai W, et al
    Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.
    Leuk Lymphoma. 2022 Jul 25:1-4. doi: 10.1080/10428194.2022.2100369.

  71. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.

  72. SEIDEL S, Kowalski T, Nilius-Eliliwi V, Schroers R, et al
    Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients >/=80 years treated with high-dose methotrexate-based chemotherapy.
    Leuk Lymphoma. 2022 Jul 20:1-7. doi: 10.1080/10428194.2022.2100371.
    PubMed     Abstract available

  73. ON S, Chang A
    Treatment of lymphoma with rituximab and chemotherapy during pregnancy.
    Leuk Lymphoma. 2022 Jul 20:1-8. doi: 10.1080/10428194.2022.2100368.
    PubMed     Abstract available

  74. ERIKA HAYDU J, Abramson JS
    CAR T-cells in relapsed Burkitt lymphoma - a promising test drive in a rare disease.
    Leuk Lymphoma. 2022 Jul 20:1-2. doi: 10.1080/10428194.2022.2102625.

  75. ZHANG Q, Tao R, Li Z, Guo H, et al
    A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.
    Leuk Lymphoma. 2022 Jul 19:1-4. doi: 10.1080/10428194.2022.2074985.

  76. LI L, Yang C, Aruna, Zhou Q, et al
    Functional evaluation of various ICAM3 transcript variants in diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2022 Jul 18:1-10. doi: 10.1080/10428194.2022.2092861.
    PubMed     Abstract available

  77. SASSE S, Brockelmann PJ, Momotow J, Plutschow A, et al
    AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
    Leuk Lymphoma. 2022 Jul 18:1-8. doi: 10.1080/10428194.2022.2095623.
    PubMed     Abstract available

  78. YAMSHON S, Jing-Mei H
    Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target.
    Leuk Lymphoma. 2022 Jul 12:1-2. doi: 10.1080/10428194.2022.2092862.

  79. RAMALINGAM TR, Muthu A, Lakshmanan A, Narla S, et al
    Role of high acquisition flow cytometry in the detection of marrow involvement in patients with extramedullary B cell non-Hodgkins lymphoma: a comparison with marrow aspirate cytology, trephine biopsy, and PET.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2092858.
    PubMed     Abstract available

  80. PANAITE L, Wu QV, Voutsinas J, Mullane E, et al
    Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
    Leuk Lymphoma. 2022 Jul 9:1-5. doi: 10.1080/10428194.2022.2095632.
    PubMed     Abstract available

  81. BOMMIER C, Ruggiu M, Monegier A, Zucca E, et al
    Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials.
    Leuk Lymphoma. 2022;63:1544-1555.
    PubMed     Abstract available

  82. JUNG JM, Lee MY, Won CH, Chang SE, et al
    Hyperpigmented mycosis fungoides: a retrospective and comparative analysis with other subtypes of mycosis fungoides.
    Leuk Lymphoma. 2022;63:1598-1606.
    PubMed     Abstract available

    June 2022
  83. STUVER R, Lewis NE, Ewalt MD, Dogan A, et al
    First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone.
    Leuk Lymphoma. 2022 Jun 25:1-4. doi: 10.1080/10428194.2022.2092860.

  84. CHAHAL M, Hayden A, Savage KJ, Villa D, et al
    Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jun 24:1-4. doi: 10.1080/10428194.2022.2087071.

  85. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.

  86. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.

  87. QUALLS D, Kumar A, Epstein-Peterson ZD
    Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Leuk Lymphoma. 2022 Jun 15:1-13. doi: 10.1080/10428194.2022.2086244.
    PubMed     Abstract available

  88. ERIKSEN PRG, Clasen-Linde E, Brown PN, Haunstrup L, et al
    NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980-2017: a nationwide cohort study.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2087069.
    PubMed     Abstract available

  89. LEVY M, Dupuis J, Charpy C, Martin A, et al
    Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
    Leuk Lymphoma. 2022 Jun 10:1-7. doi: 10.1080/10428194.2022.2086248.
    PubMed     Abstract available

  90. TEO YH, Teo YN, Khoo LP, Chang EWY, et al
    Clinicopathological factors affecting prognosis in marginal zone lymphoma in Asian patients: a cohort study.
    Leuk Lymphoma. 2022 Jun 10:1-4. doi: 10.1080/10428194.2022.2086242.

  91. SEITTER SJ, McClelland PH, Ahlman MA, Goff SL, et al
    Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
    Leuk Lymphoma. 2022 Jun 9:1-5. doi: 10.1080/10428194.2022.2076853.

  92. ALLEN PB, Goyal S, Switchenko J, Tarabadkar E, et al
    Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
    Leuk Lymphoma. 2022 Jun 7:1-8. doi: 10.1080/10428194.2022.2081324.
    PubMed     Abstract available

  93. ARULOGUN SO, Abbasi MA, Pomplun S, O'Neill AT, et al
    Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenstrom Macroglobulinaemia.
    Leuk Lymphoma. 2022;63:1496-1499.

  94. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    PubMed     Abstract available

  95. GE J, Xia Y, Sun Z, Zhang L, et al
    Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
    Leuk Lymphoma. 2022;63:1369-1374.
    PubMed     Abstract available

    May 2022
  96. BERGER T, Geiger KR, Yeshurun M, Gafter-Gvili A, et al
    Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study.
    Leuk Lymphoma. 2022 May 28:1-8. doi: 10.1080/10428194.2022.2081325.
    PubMed     Abstract available

  97. TARIQ H
    Classic Hodgkin lymphoma cloaked in an intense sarcoid-like reaction.
    Leuk Lymphoma. 2022 May 27:1-4. doi: 10.1080/10428194.2022.2081848.

  98. MAN J, Wang H, Qian X, Chen L, et al
    TCF3 protein was highly expressed in pediatric Burkitt lymphoma and predicts poor prognosis: a single-center study.
    Leuk Lymphoma. 2022 May 26:1-8. doi: 10.1080/10428194.2022.2076852.
    PubMed     Abstract available

  99. STRUSSMANN T, Wasch R, Scherer F, Mutter JA, et al
    A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin.
    Leuk Lymphoma. 2022 May 20:1-3. doi: 10.1080/10428194.2022.2074991.

  100. GORDON MJ, Sureda A, Westin JR
    Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Leuk Lymphoma. 2022 May 12:1-11. doi: 10.1080/10428194.2022.2068007.
    PubMed     Abstract available

  101. LO AC, Holloway CL, Savage KJ, Sehn LH, et al
    Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review.
    Leuk Lymphoma. 2022 May 5:1-4. doi: 10.1080/10428194.2022.2060505.

  102. EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
    Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
    Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
    PubMed     Abstract available

  103. LEBEL E, Goldschmidt N, Siegal T, Lossos A, et al
    Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
    Leuk Lymphoma. 2022 May 2:1-7. doi: 10.1080/10428194.2022.2064996.
    PubMed     Abstract available

    April 2022
  104. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    PubMed     Abstract available

  105. PHAM TM, Quy PN, Amin K, Walker E, et al
    Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
    Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
    PubMed     Abstract available

  106. PUCKRIN R, Chua N, Shafey M, Stewart DA, et al
    Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
    Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2068005.
    PubMed     Abstract available

  107. JUUL MB, Jelicic J, Anru PL, Engberg H, et al
    Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.
    Leuk Lymphoma. 2022 Apr 18:1-10. doi: 10.1080/10428194.2022.2064982.
    PubMed     Abstract available

  108. MAZIARZ RT, Yang H, Liu Q, Wang T, et al
    Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Leuk Lymphoma. 2022 Apr 14:1-11. doi: 10.1080/10428194.2022.2060503.
    PubMed     Abstract available

  109. SCHUSTER SJ, Zhang J, Yang H, Agarwal A, et al
    Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
    Leuk Lymphoma. 2022;63:845-854.
    PubMed     Abstract available

  110. DOI Y, Yokota T, Shibayama H, Matsumoto K, et al
    A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement.
    Leuk Lymphoma. 2022;63:1013-1015.

    March 2022
  111. LO AC, Major A, Super L, Appel B, et al
    Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW).
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053533.

  112. LIU L, Adlowitz DG, Rock P, Casulo C, et al
    Hypergammaglobulinemia as a presenting feature of Mantle cell lymphoma.
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2056177.

  113. WANG W, Mai B, Ali H, Chen L, et al
    Uncommon histiocyte-rich pseudotumor after chemotherapy in peripheral T-cell lymphoma.
    Leuk Lymphoma. 2022 Mar 31:1-3. doi: 10.1080/10428194.2022.2056176.

  114. RIBERA JM, Garcia O, Buendia-Urena B, Terol MJ, et al
    Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.
    Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053531.

  115. ZHOU J, Huang J, Xiao M, Wang Y, et al
    Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2022 Mar 11:1-9. doi: 10.1080/10428194.2022.2045595.
    PubMed     Abstract available

  116. BEN BAROUCH S, Bhella S, Kridel R, Kukreti V, et al
    Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.
    Leuk Lymphoma. 2022 Mar 9:1-8. doi: 10.1080/10428194.2022.2047674.
    PubMed     Abstract available

  117. KIM MS, Banerjee T, Chen A, Danilov A, et al
    A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma.
    Leuk Lymphoma. 2022 Mar 9:1-3. doi: 10.1080/10428194.2022.2045598.

  118. RODRIGUEZ-HERNANDEZ A, Giulino-Roth L
    The ABVD's of cooperative trials in pediatric Hodgkin lymphoma: The India experience.
    Leuk Lymphoma. 2022 Mar 6:1-3. doi: 10.1080/10428194.2022.2045602.

  119. MOORE DC, Elmes JB, Strassels SA, Patel JN, et al
    Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.
    Leuk Lymphoma. 2022 Mar 6:1-2. doi: 10.1080/10428194.2022.2045601.

  120. FITZGERALD KN, Quesada AE, von Keudell G, Raj S, et al
    CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas.
    Leuk Lymphoma. 2022;63:751-754.

    February 2022
  121. SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
    PubMed     Abstract available

  122. WANG WJ, Omo-Ogboi AC, Rivera Rivera X, Moosvi AM, et al
    Bone primary, spindle cell variant of diffuse large B-cell lymphoma presenting in the femur from a Paget's disease patient.
    Leuk Lymphoma. 2022 Feb 27:1-3. doi: 10.1080/10428194.2022.2043305.

  123. MEHTA-SHAH N, Bartlett NL, Kahl B, Watkins MP, et al
    COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Leuk Lymphoma. 2022 Feb 27:1-5. doi: 10.1080/10428194.2022.2038377.

  124. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available

  125. BARR PM, Smith S, Roschewski M, O'Brien SM, et al
    Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 24:1-5. doi: 10.1080/10428194.2022.2043301.

  126. TAN JY, Qiu TY, Chiang J, Tan YH, et al
    Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
    Leuk Lymphoma. 2022 Feb 19:1-11. doi: 10.1080/10428194.2022.2027402.
    PubMed     Abstract available

  127. KARAKATSANIS S, Panitsas F, Arapaki M, Galopoulos D, et al
    Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance.
    Leuk Lymphoma. 2022 Feb 19:1-14. doi: 10.1080/10428194.2021.2010054.
    PubMed     Abstract available

  128. OGASAWARA M, Miyashita M, Yamagishi Y, Ota S, et al
    Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma.
    Leuk Lymphoma. 2022 Feb 15:1-5. doi: 10.1080/10428194.2022.2038371.

  129. CABIRTA A, Hidalgo-Gomez G, Marin-Niebla A, Gallur L, et al
    Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 7:1-4. doi: 10.1080/10428194.2022.2034158.

  130. BOND DA, Huang Y, Christian BA, Jaglowski S, et al
    A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 6:1-4. doi: 10.1080/10428194.2022.2034154.

  131. WANG A, Cirrone F, De Los Reyes FA, Papadopoulos J, et al
    High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
    Leuk Lymphoma. 2022 Feb 4:1-8. doi: 10.1080/10428194.2021.2024818.
    PubMed     Abstract available

  132. MELODY M, Gandhi S, Saunders H, Abdel-Rahman Z, et al
    Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.
    Leuk Lymphoma. 2022 Feb 3:1-6. doi: 10.1080/10428194.2022.2030475.
    PubMed     Abstract available

  133. BAJWA A, Huang Y, Li R, Denlinger N, et al
    Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2022 Feb 3:1-4. doi: 10.1080/10428194.2022.2032039.

  134. FISCHER T, Ni A, Bantilan KS, Soumerai JD, et al
    The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.
    Leuk Lymphoma. 2022 Feb 3:1-10. doi: 10.1080/10428194.2021.2010058.
    PubMed     Abstract available

  135. LUCIJANIC M, Huzjan Korunic R, Sedinic M, Kovacevic S, et al
    Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes.
    Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034160.
    PubMed     Abstract available

  136. NAKA R, Tada K, Kaneko H, Nagata O, et al
    Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (ritu
    Leuk Lymphoma. 2022 Feb 2:1-4. doi: 10.1080/10428194.2022.2032040.

    Ferritin, sex, and the wildfire of inflammation in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Feb 2:1-3. doi: 10.1080/10428194.2022.2034161.

  138. BELLESI S, Sali M, Maiolo E, Pereyra Boza MDC, et al
    Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment.
    Leuk Lymphoma. 2022 Feb 1:1-5. doi: 10.1080/10428194.2022.2032042.

  139. KADDU-MULINDWA D, Lesan V, Berdel C, Stilgenbauer S, et al
    Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
    Leuk Lymphoma. 2022;63:326-334.
    PubMed     Abstract available

  140. RAMBURAN A, Kriel R, Govender D
    Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations.
    Leuk Lymphoma. 2022;63:370-376.
    PubMed     Abstract available

  141. DUELL J, Obr A, Augustin M, Endell J, et al
    CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
    Leuk Lymphoma. 2022;63:468-472.

    January 2022
  142. CAMUS V, Viennot M, Leveque E, Viailly PJ, et al
    Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.
    Leuk Lymphoma. 2022 Jan 25:1-11. doi: 10.1080/10428194.2021.2010060.
    PubMed     Abstract available

  143. FERRARI A, Arniani S, Crescenzi B, Ascani S, et al
    High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jan 19:1-7. doi: 10.1080/10428194.2021.2024821.
    PubMed     Abstract available

  144. KIM DW, Bukhari A, Lutfi F, Zafforoni F, et al
    Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2022 Jan 19:1-9. doi: 10.1080/10428194.2021.2024817.
    PubMed     Abstract available

  145. WADA F, Shimomura Y, Kamijo K, Yamashita D, et al
    Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.
    Leuk Lymphoma. 2022 Jan 19:1-4. doi: 10.1080/10428194.2021.2024820.

  146. PANAYIOTIDIS P, Tumyan G, Thieblemont C, Ptushkin VV, et al
    A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenstrom's macroglobulinemia.
    Leuk Lymphoma. 2022 Jan 19:1-12. doi: 10.1080/10428194.2021.2015765.
    PubMed     Abstract available

  147. CHOHAN K, Ansell SM
    Current salvage therapies in Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jan 17:1-14. doi: 10.1080/10428194.2021.2024819.
    PubMed     Abstract available

  148. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    PubMed     Abstract available

  149. HEGER JM, Borchmann S
    Coming of age: the evolving role of circulating tumor DNA in malignant lymphoma.
    Leuk Lymphoma. 2022 Jan 12:1-3. doi: 10.1080/10428194.2022.2027404.

  150. HYBEL TE, Vase MO, Lauridsen KL, Enemark MB, et al
    CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus.
    Leuk Lymphoma. 2022 Jan 12:1-5. doi: 10.1080/10428194.2021.2023741.

  151. CIOS KJ, Huda TI, Eakins RA, Mihyu MM, et al
    Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2022 Jan 12:1-9. doi: 10.1080/10428194.2021.2020781.
    PubMed     Abstract available

  152. BURGER JA, Robak T, Demirkan F, Bairey O, et al
    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
    PubMed     Abstract available

  153. HENRY M, Buck S, Al-Qanber B, Gadgeel M, et al
    Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway.
    Leuk Lymphoma. 2022 Jan 8:1-8. doi: 10.1080/10428194.2021.2023744.
    PubMed     Abstract available

  154. ABRAHAO R, Brunson AM, Kahn JM, Li QW, et al
    Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.
    Leuk Lymphoma. 2022 Jan 6:1-11. doi: 10.1080/10428194.2021.2020775.
    PubMed     Abstract available

  155. MINSON A, Hofman M, Dickinson M
    A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse.
    Leuk Lymphoma. 2022;63:1-4.
    PubMed     Abstract available

  156. SEMCHENKOVA A, Zhogov V, Rudneva A, Potapenko L, et al
    Immune reconstitution following rituximab-based immunochemotherapy in pediatric patients with B-cell non-Hodgkin lymphomas.
    Leuk Lymphoma. 2022;63:217-221.

  157. COSTA PA, Espejo-Freire AP, Fan KC, Albini TA, et al
    Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.
    Leuk Lymphoma. 2022;63:239-242.

  158. OTHMAN T, Moskoff BN, Esteghamat N, Hoeg RT, et al
    Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
    Leuk Lymphoma. 2022;63:231-234.

  159. ZHANG Y, Seminario-Vidal L, Varnadoe C, Lu Y, et al
    Clinical characteristics and prognostic factors of 70 patients with Sezary syndrome: a single-institutional experience at Moffitt cancer center.
    Leuk Lymphoma. 2022;63:109-116.
    PubMed     Abstract available

  160. PIROSA MC, Zhang L, Hitz F, Novak U, et al
    A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas.
    Leuk Lymphoma. 2022;63:117-123.
    PubMed     Abstract available

    December 2021
  161. GOUNI S, Strati P, Toruner G, Aradhya A, et al
    Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Dec 31:1-12. doi: 10.1080/10428194.2021.2020782.
    PubMed     Abstract available

  162. NAKAMURA N, Kanemura N, Lee S, Fujita K, et al
    Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2021 Dec 29:1-8. doi: 10.1080/10428194.2021.2020777.
    PubMed     Abstract available

  163. FORTUNY J, Plana E, Kaye JA
    Serum lipid trajectories in the years before a lymphoma diagnosis.
    Leuk Lymphoma. 2021 Dec 29:1-13. doi: 10.1080/10428194.2021.1992618.
    PubMed     Abstract available

  164. LEBEL E, Vainstein V, Ashkenazi M, Zimran E, et al
    Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
    Leuk Lymphoma. 2021 Dec 29:1-8. doi: 10.1080/10428194.2021.2018580.
    PubMed     Abstract available

  165. AMAADOR K, Vos JMI, Pals ST, Kraan W, et al
    Discriminating between Waldenstrom macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.
    Leuk Lymphoma. 2021 Dec 27:1-10. doi: 10.1080/10428194.2021.2018584.
    PubMed     Abstract available

  166. ZHANG C, Mi L, Wu M, Liu W, et al
    Angioimmunoblastic T-cell lymphoma: treatment strategies and prognostic factors from a retrospective multicenter study in China.
    Leuk Lymphoma. 2021 Dec 27:1-8. doi: 10.1080/10428194.2021.2015586.
    PubMed     Abstract available

  167. GIEFING M, Gearhart MD, Schneider M, Overbeck B, et al
    Loss of function mutations of BCOR in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Dec 27:1-11. doi: 10.1080/10428194.2021.2015587.
    PubMed     Abstract available

  168. DE GROOT FA, de Haan LM, de Groen RAL, Heijmen L, et al
    Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing.
    Leuk Lymphoma. 2021 Dec 21:1-5. doi: 10.1080/10428194.2021.2015589.

  169. TRABOLSI A, Alderuccio JP, Florindez J, Rodriguez G, et al
    Marginal zone lymphoma of the colon: case series from a single center and SEER data review.
    Leuk Lymphoma. 2021 Dec 19:1-7. doi: 10.1080/10428194.2021.2015766.
    PubMed     Abstract available

  170. KORSOS V, Vallee A, Rys R, Probst S, et al
    Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab.
    Leuk Lymphoma. 2021 Dec 16:1-5. doi: 10.1080/10428194.2021.2012571.

  171. KUMAR AJ, Chao CR, Rodday AM, Chang H, et al
    Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
    Leuk Lymphoma. 2021 Dec 10:1-8. doi: 10.1080/10428194.2021.2012660.
    PubMed     Abstract available

  172. JAIN S, Bakhshi S, Seth R, Verma N, et al
    Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01.
    Leuk Lymphoma. 2021 Dec 9:1-8. doi: 10.1080/10428194.2021.2012659.
    PubMed     Abstract available

  173. HALWANI AS, Panizo C, Isufi I, Herrera AF, et al
    Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
    Leuk Lymphoma. 2021 Dec 6:1-13. doi: 10.1080/10428194.2021.2010057.
    PubMed     Abstract available

  174. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    PubMed     Abstract available

  175. WITTE HM, Merz H, Bernd HW, Bauer A, et al
    Comparative analysis of international prognostic indices in gray-zone lymphoma.
    Leuk Lymphoma. 2021 Dec 2:1-9. doi: 10.1080/10428194.2021.2010067.
    PubMed     Abstract available

  176. GHAZZAUI N, Ferrad M, Issaoui H, Lecardeur S, et al
    HDAC recruitment in the IgH locus 3' regulatory region is different between mature B-cells and mature B-cell lymphomas.
    Leuk Lymphoma. 2021;62:3511-3515.

  177. STABER PB, Jurczak W, Greil R, Vucinic V, et al
    Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma. 2021;62:3440-3451.
    PubMed     Abstract available

  178. PEARSE WB, Petrich AM, Gordon LI, Karmali R, et al
    A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
    Leuk Lymphoma. 2021;62:3493-3500.
    PubMed     Abstract available

  179. WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
    Idelalisib immune-related toxicity is associated with improved treatment response.
    Leuk Lymphoma. 2021;62:2915-2920.
    PubMed     Abstract available

  180. MINSON A, Dickinson M
    Glofitamab CD20-TCB bispecific antibody.
    Leuk Lymphoma. 2021;62:3098-3108.
    PubMed     Abstract available

    November 2021
  181. MOZAS P, Rivero A, Rivas-Delgado A, Nadeu F, et al
    The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma.
    Leuk Lymphoma. 2021 Nov 29:1-8. doi: 10.1080/10428194.2021.2010064.
    PubMed     Abstract available

  182. LIU H, Li P, Zhao A, Lei W, et al
    Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.
    Leuk Lymphoma. 2021 Nov 28:1-4. doi: 10.1080/10428194.2021.2010062.

  183. GORDON MJ, Westin JR
    Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
    Leuk Lymphoma. 2021 Nov 28:1-11. doi: 10.1080/10428194.2021.2008383.
    PubMed     Abstract available

  184. PAK TK, Dixon BN, Buege MJ, Dao PH, et al
    Successful implementation of outpatient R +/- DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience.
    Leuk Lymphoma. 2021 Nov 16:1-9. doi: 10.1080/10428194.2021.2002318.
    PubMed     Abstract available

  185. SESHADRI MR, Melnick AM
    Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Nov 16:1-10. doi: 10.1080/10428194.2021.1999444.
    PubMed     Abstract available

  186. SHAH H, Jang H, Singh P, Kosti J, et al
    Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.
    Leuk Lymphoma. 2021 Nov 15:1-8. doi: 10.1080/10428194.2021.2002322.
    PubMed     Abstract available

  187. SOLEIMANI A, Navarro A, Liu D, Herman SEM, et al
    CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
    Leuk Lymphoma. 2021 Nov 15:1-7. doi: 10.1080/10428194.2021.2002317.
    PubMed     Abstract available

  188. MELANI C, Wilson WH
    Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure.
    Leuk Lymphoma. 2021 Nov 11:1-3. doi: 10.1080/10428194.2021.2002323.

  189. REISS SN, Yerram P, Modelevsky L, Grommes C, et al
    Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
    Leuk Lymphoma. 2021 Nov 10:1-6. doi: 10.1080/10428194.2021.1998481.
    PubMed     Abstract available

  190. LI M, Ding N, Mi L, Shi Y, et al
    Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Leuk Lymphoma. 2021 Nov 9:1-10. doi: 10.1080/10428194.2021.1999441.
    PubMed     Abstract available

  191. MACKLIN-DOHERTY A, Jones M, Coulson P, Bruce C, et al
    Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment.
    Leuk Lymphoma. 2021 Nov 5:1-11. doi: 10.1080/10428194.2021.1999445.
    PubMed     Abstract available

  192. AVGERINOU G, Stefanaki K, Liapis K, Kostopoulos IV, et al
    Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.
    Leuk Lymphoma. 2021 Nov 2:1-11. doi: 10.1080/10428194.2021.1998480.
    PubMed     Abstract available

  193. LEVY A, Guidez S, Debiais C, Princet I, et al
    Waldenstrom macroglobulinemia and relationship to immune deficiency.
    Leuk Lymphoma. 2021;62:2665-2670.
    PubMed     Abstract available

    October 2021
  194. AUSSEDAT G, Maucort-Boulch D, Rey P, Safar V, et al
    Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
    Leuk Lymphoma. 2021 Oct 31:1-9. doi: 10.1080/10428194.2021.1998483.
    PubMed     Abstract available

  195. KIM HD, Cho H, Sohn BS, Park CS, et al
    Prognostic significance of serum beta2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.
    Leuk Lymphoma. 2021 Oct 26:1-7. doi: 10.1080/10428194.2021.1971220.
    PubMed     Abstract available

  196. MUSIU P, Quattrocchi L, Barberi W, Della Starza I, et al
    Donor cell derived mantle cell lymphoma in a HSCT sibling donor-recipient pair: intrinsic biological clock in lymphomagenesis.
    Leuk Lymphoma. 2021 Oct 25:1-4. doi: 10.1080/10428194.2021.1984456.

  197. IYER SG, Kuker R, Florindez JA, Saul E, et al
    A single-center analysis of patients with extranodal marginal zone lymphoma of the breast.
    Leuk Lymphoma. 2021 Oct 21:1-8. doi: 10.1080/10428194.2021.1992764.
    PubMed     Abstract available

  198. PUCKRIN R, Ghosh S, Peters A, Stewart D, et al
    Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities.
    Leuk Lymphoma. 2021 Oct 21:1-8. doi: 10.1080/10428194.2021.1992762.
    PubMed     Abstract available

  199. KONG D, Li Y, Fu C, Hou M, et al
    Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.
    Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992766.

  200. NG DZ, Lee CY, Lam WW, Tong AK, et al
    Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the DeltaSUVmax method.
    Leuk Lymphoma. 2021 Oct 19:1-4. doi: 10.1080/10428194.2021.1992624.
    PubMed     Abstract available

  201. YIN G, Man C, Cheng W, Gao X, et al
    The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2021 Oct 18:1-8. doi: 10.1080/10428194.2021.1992623.
    PubMed     Abstract available

  202. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available

  203. LEBLANC MR, Zimmerman S, LeBlanc TW, Bryant AL, et al
    Persistent fatigue among long-term non-Hodgkin lymphoma survivors.
    Leuk Lymphoma. 2021 Oct 6:1-9. doi: 10.1080/10428194.2021.1984450.
    PubMed     Abstract available

  204. MALFONA F, Testi AM, Moleti ML, Petrucci L, et al
    Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Leuk Lymphoma. 2021 Oct 6:1-4. doi: 10.1080/10428194.2021.1978091.

  205. TARIQ H, Pearse W, Moravek MR, Gao J, et al
    Refractory hemophagocytic lymphohistiocytosis in an adult patient with occult ALK-Positive anaplastic large cell lymphoma and a heterozygous MEFV mutation.
    Leuk Lymphoma. 2021 Oct 6:1-4. doi: 10.1080/10428194.2021.1984458.

  206. KLAIRMONT MM, Ward N
    Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes.
    Leuk Lymphoma. 2021 Oct 6:1-3. doi: 10.1080/10428194.2021.1984457.

  207. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.

  208. BRUMFIEL CM, Patel MH, DiCaudo DJ, Rosenthal AC, et al
    Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
    Leuk Lymphoma. 2021;62:2554-2555.

    September 2021
  209. ZHANG H, Liu M, Li Q, Lyu C, et al
    Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system.
    Leuk Lymphoma. 2021 Sep 29:1-9. doi: 10.1080/10428194.2021.1986216.
    PubMed     Abstract available

    Closing the diagnostic gap: increasing recognition of bone mineral density loss after treatment of lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-2. doi: 10.1080/10428194.2021.1984461.

  211. ALDERUCCIO JP, Lossos IS
    NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
    Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
    PubMed     Abstract available

  212. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    PubMed     Abstract available

  213. SAWALHA Y, Radivoyevitch T, Jia X, Tullio K, et al
    The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2021 Sep 15:1-9. doi: 10.1080/10428194.2021.1978085.
    PubMed     Abstract available

  214. GONZALEZ DE VILLAMBROSIA S, Bastos M, Palanca JM, Cruz JG, et al
    BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.
    Leuk Lymphoma. 2021 Sep 11:1-8. doi: 10.1080/10428194.2021.1975189.
    PubMed     Abstract available

  215. KANAS G, Ge W, Quek RGW, Keeven K, et al
    Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.
    Leuk Lymphoma. 2021 Sep 11:1-10. doi: 10.1080/10428194.2021.1975188.
    PubMed     Abstract available

  216. HSU A, Kurt H, Zayac AS, Olszewski AJ, et al
    CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
    Leuk Lymphoma. 2021 Sep 1:1-12. doi: 10.1080/10428194.2021.1973670.
    PubMed     Abstract available

  217. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021;62:2161-2168.
    PubMed     Abstract available

  218. URYU H, Mishima Y, Tsuyama N, Yokoyama M, et al
    Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
    Leuk Lymphoma. 2021;62:2141-2150.
    PubMed     Abstract available

    August 2021
  219. LOPEZ-GUILLERMO A, Canales MA, Dlouhy I, Mercadal S, et al
    A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
    Leuk Lymphoma. 2021 Aug 30:1-8. doi: 10.1080/10428194.2021.1971216.
    PubMed     Abstract available

  220. HSU CH, Yang CS, Chen YJ, Lin TL, et al
    Primary neurolymphomatosis in extranodal natural killer/T-cell lymphoma diagnosed by skin biopsy.
    Leuk Lymphoma. 2021 Aug 27:1-3. doi: 10.1080/10428194.2021.1971221.

  221. CHERNG HJ, Chuang HH, Steiner R, Fayad L, et al
    A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 26:1-10. doi: 10.1080/10428194.2021.1971223.
    PubMed     Abstract available

  222. LANDSBURG DJ, Nasta SD, Gerson JN, Svoboda J, et al
    Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy.
    Leuk Lymphoma. 2021 Aug 26:1-4. doi: 10.1080/10428194.2021.1971224.

  223. HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
    Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.

  224. DENKER S, Bittner A, Frick M, Kase J, et al
    Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
    Leuk Lymphoma. 2021 Aug 20:1-9. doi: 10.1080/10428194.2021.1964024.
    PubMed     Abstract available

  225. ALDERUCCIO JP, Kuker RA, Barreto-Coelho P, Martinez BM, et al
    Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 20:1-11. doi: 10.1080/10428194.2021.1966786.
    PubMed     Abstract available

  226. AKYUZ N, Penas EMM, Janjetovic S, Loges S, et al
    Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case.
    Leuk Lymphoma. 2021 Aug 18:1-5. doi: 10.1080/10428194.2021.1966783.

  227. WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.

  228. AL ROWAIS F, Al Rabeh R, Al Mahasnah E, Al Shami A, et al
    Promising activity of single agent nivolumab followed by low-dose whole brain radiotherapy in isolated central nervous system relapse of Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Aug 12:1-4. doi: 10.1080/10428194.2021.1964025.

  229. BENDIG S, Walter W, Meggendorfer M, Bar C, et al
    Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma.
    Leuk Lymphoma. 2021 Aug 12:1-10. doi: 10.1080/10428194.2021.1964021.
    PubMed     Abstract available

  230. NASTOUPIL LJ, Neelapu SS, Davis RE, Samaniego F, et al
    Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K beta/delta in relapsed refractory B cell lymphoma.
    Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957874.
    PubMed     Abstract available

  231. JOHNSON WT, Kartan S, Sokol K, Nikbakht N, et al
    Clinical characteristics and outcomes of black patients with mycosis fungoides and Sezary syndrome: a subgroup analysis of the phase III MAVORIC trial.
    Leuk Lymphoma. 2021;62:1877-1883.
    PubMed     Abstract available

    July 2021
  232. PLATTEL WJ, Bergamasco A, Trinchese F, Gavini F, et al
    Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Jul 29:1-13. doi: 10.1080/10428194.2021.1957865.
    PubMed     Abstract available

  233. TOBIN JWD, Crothers A, Ma TE, Mollee P, et al
    A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.
    Leuk Lymphoma. 2021 Jul 29:1-9. doi: 10.1080/10428194.2021.1957866.
    PubMed     Abstract available

  234. HORWITZ S, Zinzani PL, Bagot M, Kim YH, et al
    Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Leuk Lymphoma. 2021 Jul 26:1-10. doi: 10.1080/10428194.2021.1953007.
    PubMed     Abstract available

  235. TAO Y, He X, Qin Y, Liu P, et al
    Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Jul 23:1-11. doi: 10.1080/10428194.2021.1953015.
    PubMed     Abstract available

  236. DURANI U, Ansell SM
    CD5+ diffuse large B-cell lymphoma: a narrative review.
    Leuk Lymphoma. 2021 Jul 21:1-9. doi: 10.1080/10428194.2021.1953010.
    PubMed     Abstract available

  237. BAEK GT, Mathis NJ, Perissinotti AJ, Marini BL, et al
    Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 15:1-9. doi: 10.1080/10428194.2021.1953014.
    PubMed     Abstract available

  238. SONG Y, Li J, Wang S, Zhou Z, et al
    The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jul 14:1-8. doi: 10.1080/10428194.2021.1948035.
    PubMed     Abstract available

  239. LAPIERRE L, Pericart S, Protin C, Borel C, et al
    Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 13:1-3. doi: 10.1080/10428194.2021.1950711.

  240. ALLIOUX F, Gandhi D, Vilque JP, Nganoa C, et al
    End-of-treatment (18)F-FDG PET/CT in diffuse large B cell lymphoma patients: DeltaSUV outperforms Deauville score.
    Leuk Lymphoma. 2021 Jul 5:1-9. doi: 10.1080/10428194.2021.1948028.
    PubMed     Abstract available

  241. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available

  242. MANSO R, Rodriguez-Perales S, Torres-Ruiz R, Santonja C, et al
    PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
    Leuk Lymphoma. 2021;62:1648-1656.
    PubMed     Abstract available

    June 2021
  243. MOU E, Falchi L, Sundaram V, Abramson JS, et al
    Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
    Leuk Lymphoma. 2021 Jun 26:1-9. doi: 10.1080/10428194.2021.1941936.
    PubMed     Abstract available

  244. XIAO Z, Mo Y, Long W, Li R, et al
    Value of baseline and end of chemotherapy (18)F-FDG PET/CT in pediatric patients with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 24:1-9. doi: 10.1080/10428194.2021.1941933.
    PubMed     Abstract available

  245. ELGAAFARY S, Lopez C, Nagel I, Vater I, et al
    Molecular characterization of Burkitt lymphoma in the breast or ovary.
    Leuk Lymphoma. 2021 Jun 24:1-10. doi: 10.1080/10428194.2021.1907374.
    PubMed     Abstract available

  246. OU YC, Tang Z, Novotny W, Cohen A, et al
    Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 Jun 23:1-13. doi: 10.1080/10428194.2021.1929961.
    PubMed     Abstract available

  247. CASTILLO JJ, Beltran BE, Malpica L, Marques-Piubelli ML, et al
    Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
    Leuk Lymphoma. 2021 Jun 21:1-9. doi: 10.1080/10428194.2021.1941929.
    PubMed     Abstract available

  248. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.

  249. MESSMER M, Wagner-Johnston N
    COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941939.

  250. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed     Abstract available

  251. KARALEXI MA, Pourtsidis A, Panagopoulou P, Moschovi M, et al
    Overall and event-free survival of childhood lymphoma in Greece: analysis of harmonized clinical data over a 24-year active registration period.
    Leuk Lymphoma. 2021 Jun 11:1-13. doi: 10.1080/10428194.2021.1907376.
    PubMed     Abstract available

  252. MOZESSOHN L, Zhang L, Odejide OO, Chen R, et al
    Prognostic value of disease risk score versus gait speed in older adults with lymphoma.
    Leuk Lymphoma. 2021 Jun 11:1-8. doi: 10.1080/10428194.2021.1938029.
    PubMed     Abstract available

  253. BRAM EDNERSSON S, Stern M, Fagman H, Nilsson-Ehle H, et al
    Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.
    Leuk Lymphoma. 2021 Jun 11:1-14. doi: 10.1080/10428194.2021.1913147.
    PubMed     Abstract available

  254. MINSON A, Dickinson M
    Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 9:1-3. doi: 10.1080/10428194.2021.1938033.

  255. SORIGUE M, Sancho JM
    The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 8:1-4. doi: 10.1080/10428194.2021.1929965.

  256. CHEN Q, Liu S, Zhang K, Yu B, et al
    Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1beta release in NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jun 3:1-9. doi: 10.1080/10428194.2021.1933472.
    PubMed     Abstract available

  257. RODRIGUES JM, Porwit A, Hassan M, Ek S, et al
    Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
    Leuk Lymphoma. 2021 Jun 3:1-11. doi: 10.1080/10428194.2021.1933480.
    PubMed     Abstract available

  258. TREVINO KM, Martin P, Saracino R, Leonard JP, et al
    Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis.
    Leuk Lymphoma. 2021;62:1370-1378.
    PubMed     Abstract available

  259. MOZAS P, Lopez-Guillermo A
    Response to: The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-2. doi: 10.1080/10428194.2021.1933482.

  260. ALVAREZ E, Le T, Kahn J, Winestone L, et al
    Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-7. doi: 10.1080/10428194.2021.1932873.

    May 2021
  261. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Primary thyroid lymphoma: survival analysis of SEER database (1995-2016).
    Leuk Lymphoma. 2021 May 27:1-4. doi: 10.1080/10428194.2021.1933479.

  262. ZHU X, Li W, Zhu J, Chen H, et al
    Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 25:1-9. doi: 10.1080/10428194.2021.1927017.
    PubMed     Abstract available

  263. PALOMBA ML, Jun MP, Lymp J, Nguyen A, et al
    Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686.
    PubMed     Abstract available

  264. BONZHEIM I, Quintanilla-Martinez L
    All activated signaling pathways lead to anaplastic large cell lymphoma (ALCL).
    Leuk Lymphoma. 2021 May 21:1-3. doi: 10.1080/10428194.2021.1924373.

  265. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  266. CHAPMAN J, Verdun RE, Lossos IS
    Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with MYC and MYC/BCL2 rearrangements, especially in germinal center cell-type tumors.
    Leuk Lymphoma. 2021 May 14:1-4. doi: 10.1080/10428194.2021.1927020.

  267. FAKHRI B, Yilmaz E, Gao F, Ambinder RF, et al
    Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 14:1-8. doi: 10.1080/10428194.2021.1927016.
    PubMed     Abstract available

  268. MACHAN S, Rodriguez M, Alonso-Alonso R, Manso R, et al
    Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes.
    Leuk Lymphoma. 2021 May 8:1-11. doi: 10.1080/10428194.2021.1901098.
    PubMed     Abstract available

  269. YANG J, Zhang Y, Yang P, Zhang X, et al
    A novel nomogram based on prognostic factors for predicting venous thrombosis risk in lymphoma patients.
    Leuk Lymphoma. 2021 May 8:1-9. doi: 10.1080/10428194.2021.1913149.
    PubMed     Abstract available

  270. GOYAL RK, Jain P, Nagar SP, Le H, et al
    Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 May 8:1-10. doi: 10.1080/10428194.2021.1919662.
    PubMed     Abstract available

  271. AL FEGHALI KA, Fang P, Gule-Monroe M, Milgrom S, et al
    Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
    Leuk Lymphoma. 2021 May 4:1-8. doi: 10.1080/10428194.2021.1919656.
    PubMed     Abstract available

  272. LANG N, Kuruvilla J
    Evolving management strategies for lymphomas during the COVID-19 pandemic.
    Leuk Lymphoma. 2021;62:1046-1056.
    PubMed     Abstract available

  273. WAGNER-JOHNSTON ND, Schuster SJ, deVos S, Salles G, et al
    Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Leuk Lymphoma. 2021;62:1077-1087.
    PubMed     Abstract available

  274. SEKAR A, Davids MS
    Idelalisib in indolent NHL - has it finally found its niche?
    Leuk Lymphoma. 2021;62:1029-1030.

    April 2021
  275. LUCIJANIC M, Korunic RH, Sedinic M, Kusec R, et al
    Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type.
    Leuk Lymphoma. 2021 Apr 28:1-4. doi: 10.1080/10428194.2021.1919667.

  276. CARPIO C, Iacoboni G, Villacampa G, Catala E, et al
    Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
    Leuk Lymphoma. 2021 Apr 24:1-4. doi: 10.1080/10428194.2021.1913141.

  277. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available

  278. WILSON WH, Phillips T, Popplewell L, de Vos S, et al
    Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-16. doi: 10.1080/10428194.2021.1907371.
    PubMed     Abstract available

  279. OLLIKAINEN RK, Kotkaranta PH, Kemppainen J, Teppo HR, et al
    Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-10. doi: 10.1080/10428194.2021.1913150.
    PubMed     Abstract available

    March 2021
  280. WENGE DV, Wethmar K, Mikesch JH, Reicherts C, et al
    Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.
    Leuk Lymphoma. 2021 Mar 29:1-10. doi: 10.1080/10428194.2021.1894645.
    PubMed     Abstract available

  281. ISSA DE, Dinmohamed AG, Wondergem MJ, Blommestein HM, et al
    A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands.
    Leuk Lymphoma. 2021;62:549-559.
    PubMed     Abstract available

  282. BERNING P, Lenz G
    The role of PI3K inhibitors in the treatment of malignant lymphomas.
    Leuk Lymphoma. 2021;62:517-527.
    PubMed     Abstract available

    January 2021
  283. POLPRASERT C, Takeuchi Y, Makishima H, Wudhikarn K, et al
    Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.
    Leuk Lymphoma. 2021;62:95-103.
    PubMed     Abstract available

  284. VOORHEES TJ, Kannan KK, Galeotti J, Grover N, et al
    Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation.
    Leuk Lymphoma. 2021;62:86-94.
    PubMed     Abstract available

    October 2020
  285. CUI L, Gao C, Wang CJ, Zhao XX, et al
    Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Oct 15:1-9. doi: 10.1080/10428194.2020.1832668.
    PubMed     Abstract available

    July 2020
  286. ISUFI I, Seropian S, Gowda L, Wilson LD, et al
    Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Leuk Lymphoma. 2020 Jul 9:1-7. doi: 10.1080/10428194.2020.1790555.
    PubMed     Abstract available

    June 2020
  287. STRATI P, Ahmed MA, Nastoupil LJ, Feng L, et al
    Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
    Leuk Lymphoma. 2020;61:1380-1387.
    PubMed     Abstract available

    February 2020
  288. NARAZAKI T, Shiratsuchi M, Matsushima T, Tsuda M, et al
    Clinico-pathological characteristics of primary adrenal lymphomas - potential efficacy of autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Feb 10:1-3. doi: 10.1080/10428194.2020.1725507.

    January 2020
  289. PARIKH SA, Meacham PJ, Zent CS, Evans AG, et al
    Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.
    Leuk Lymphoma. 2020 Jan 11:1-15. doi: 10.1080/10428194.2019.1709830.
    PubMed     Abstract available

    September 2019
  290. MANCONI L, Coviello E, Canale F, Giannoni L, et al
    Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
    Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.